On May 25, 2023, Camac Partners, LLC filed a preliminary proxy statement soliciting proxies and recommending the shareholders of Forte Biosciences, Inc. to vote for the election of its 2 nominees, Michael G. Hacke and Chris McIntyre, and not to vote for the 2 Company nominees, Lawrence Eichenfield and Paul A. Wagner, at the Company?s 2023 annual shareholders meeting.